If the Company determines, based on this assessment, that it is more likely than not that the fair value of the reporting unit is less than its carrying value, it performs a quantitative goodwill impairment test by comparing the reporting unit’s fair value with its carrying value.
At the closing of the acquisition of 4titude, a cash payment of $0.4 million was placed into escrow which was ascribed to the purchase price.
The Company satisfies its performance obligations by transferring a product or service either at a point in time or over time, when the transfer of control of the underlying performance obligation has occurred.
As of June 30, 2019, the unrecognized compensation cost related to restricted stock units that are expected to vest is $27.2 million and will be recognized over an estimated weighted average service period of approximately 1.7 years.
The Company applied variations of the income approach to estimate the fair values of the intangibles assets acquired.
The goodwill from this acquisition is reported within the Brooks Life Sciences segment and is not tax deductible.
The Disposition met the "held for sale" criteria and the “discontinued operation” criteria in accordance with FASB ASC 205 as of September 30, 2018.
Item 1A.
During the three months ended June 30, 2019, and the period since acquisition, net income included $3.3 million and $8.2 million, respectively, related to amortization expense of acquired intangible assets.
As part of the acquisition, the Company assumed all the assets and liabilities of Tec-Sem’s Swiss defined benefit plan, which covered substantially all its full-time employees.
 The Company allocated the purchase price of $5.2 million based on the fair value of the assets and liabilities acquired as of the acquisition date, which included $0.3 million of accounts receivable, $2.6 million of customer relationships, $2.7 million of goodwill and $0.7 million of assumed liabilities.
 The Company allocated the purchase price of $5.2 million based on the fair value of the assets and liabilities acquired as of the acquisition date, which included $0.3 million of accounts receivable, $2.6 million of customer relationships, $2.7 million of goodwill and $0.7 million of assumed liabilities.Cash inflows from operating activities of $58.2 million was comprised of $76.6 million of net earnings, including net income of $25.1 million and the impact of non-cash related charges of $51.5 million, partially offset by uses of cash of $18.4 million related to the changes in our operating assets and liabilities, net of acquisitions.
The decrease in cash and cash equivalents and marketable securities of $91.5 million was primarily attributable to net cash outflows of $442.7 million to acquire GENEWIZ, cash dividends paid of $21.7 million and capital expenditures of $15.5 million, partially offset by net cash inflows primarily from proceeds received in connection with the amendment and syndication of our incremental term loan of $331.4 million, proceeds from the sales and maturities of marketable securities of $51.5 million and net cash inflows from operating activities of $58.2 million as of June 30, 2019.
Cash, cash equivalents and marketable securities were $159.8 million at June 30, 2019 as compared to $251.2 million at September 30, 2018.
The difference in reported gross margin due to the adoption of the new revenue recognition standard was a net increase in gross profit of $0.2 million and $0.8 million during three and nine months ended June 30, 2019, respectively.
Income from continuing operations was $0.9 million for the third quarter of fiscal year 2019, as compared to $4.8 million for the corresponding period of the prior fiscal year.
Operating income was $35.4 million during the nine months ended June 30, 2019 as compared to $27.8 million for the corresponding period of the prior fiscal year.